CIK联合化疗治疗晚期食管癌的疗效观察  

Clinical effects on chemotherapy combined with CIK for patients with advanced oesophageal carcinoma

作　　者：徐本玲[1] 高全立[1] 范瑞华[1] 刘雪[1] 郭金东[1] 张成娟[1] 

机构地区：[1]河南省肿瘤医院生物治疗中心,河南郑州453000

出　　处：《河南医学研究》2010年第3期315-317,320,共4页Henan Medical Research

摘　　要：目的：探讨CIK联合FP化疗治疗进展期食管癌的可行性,安全性及近期疗效。方法：观察组21例采用CIK联合FP方案：DDP 30 mg/m^2,静滴,第1-3 d,5-FU500 mg/m^2,静滴,第1-5 d,化疗前抽血行CIK细胞培养,12-14 d培养结束后回输,21 d为1周期。对照组25例采用FP方案同观察组。观察两组患者疗效,生存质量,免疫功能的变化。结果：两组46例患者均完成治疗计划。两组均无CR病例。对照组PR 8例,SD 8例,PD 9例,有效率32%,临床获益率64%,CIK联合FP观察组,PR 10例,SD 7例,PD 4例,有效率47.6%,临床获益率80.95%。两组近期疗效有统计学差异（P〈0.05）。疗程结束后2周,观察组治疗前后患者外周血中淋巴细胞表型进行分析显示,患者免疫功能状态较治疗前有明显改善。结论：CIK联合化疗治疗食管癌是一种安全可行,有效的治疗模式。Objective： To explore the feasibility,safety,and efficacy of CIK combinated chemotherapy in the treatment of advanced oesophageal carcinoma.Methods： 21 patients were treated with CIK combined with FP regimen,5-Fu 500 mg/m^2,iv,1-5 d;DDP 30 mg/m^2,iv,1-3 d;CIK cells were induced and then were transfused back to the patients.The changes of tumor,life quality,and immunity indexes were observed.Control group only were treated with FP regimen.Results： All patients completed the therapy regimen successfully.None complete remission was obsevered in the two groups.While in the control group,the clinical benefical rate was 64%,with PR 32%. In the study group,the clinical benefical rate was 80.95%,with PR 47.6%.It has significant differences between the two groups in terms of clinical benefical rate,life quality and immunity indexes.Conclusion： CIK combinated with FP chemotherapy regimen is a safe and feasible approach to advanced oesophageal carcinoma.

关 键 词：食管癌 CIK 化疗 

分 类 号：R735.2[医药卫生—肿瘤]